AI Article Synopsis
- - Crohn's Disease can lead to the development of fistulas in about 50% of patients within 20 years, with perianal fistulizing disease affecting half of those patients, yet the exact causes remain unclear.
- - The epithelial-to-mesenchymal transition (EMT) is currently considered a key factor in the formation of these fistulas, and long-term fistulas significantly increase the risk of developing certain cancers.
- - Managing perianal fistulizing Crohn's Disease is complex and requires a team approach, combining medical and surgical treatments to improve patients' quality of life.
Article Abstract
Crohn's Disease (CD) is a chronic inflammatory disorder in which up to 50% of patients develop fistula within 20 years after the initial diagnosis, and half of these patients suffer perianal fistulizing disease. The etiopathogenesis of CD-related perianal fistula is still unclear, and its phenotypical and molecular characteristics are even more indefinite. A better understanding would be crucial to develop targeted and more effective therapeutic strategies. At present, the most accredited theory for the formation of CD-related fistula identifies the epithelial-to-mesenchymal transition (EMT) as the driving force. It has been well recognized that CD carries an increased risk of malignancy, particularly mucinous adenocarcinoma is often associated with long-standing fistula in CD patients. Despite the availability of multiple treatment options, perianal fistulizing CD represents a therapeutic challenge and is associated with an important impact on patients' quality of life. To date, the most effective management is multidisciplinary with the cooperation of gastroenterologists, surgeons, radiologists, and nutritionists and the best recommended treatment is a combination of medical and surgical approaches.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8658128 | PMC |
| http://dx.doi.org/10.3390/jcm10235548 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[New treatment targets for inflammatory bowel disease?].
Inn Med (Heidelb)
December 2024
Innere Medizin I, Universitätsklinikum Tübingen, Otfried-Müller-Straße 10, 72076, Tübingen, Deutschland.
The classic therapeutic goals of chronic inflammatory bowel disease (IBD) are, on the one hand, clinical remission and, on the other, the prevention of disease progression. The introduction of additional "targets" such as normalization of laboratory inflammation values, endoscopic and, possibly, histological mucosal healing and transmural parameters (ultrasound, magnetic resonance imaging and computed tomography) is intended to improve prognosis. A good response to therapy is usually (also) evident from these targets, although the obligatory change in medication in order to improve the prognosis if the additional treatment goals are not achieved is not evidence-based.
View Article and Find Full Text PDFManagement of Perianal Fistulas Associated with Crohn Disease: A Nurse's Perspective.
Gastroenterol Nurs
November 2024
Atypical Presentation of Small Bowel Crohn's Disease: Case Report of Musculoskeletal and Hepatic Complications Without Gastrointestinal Symptoms.
J Inflamm Res
December 2024
Department of Colorectal Surgery, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310016, People's Republic of China.
Herein, we described a case of small bowel Crohn's disease with recurrent, unexplained fevers, pain in the right lower back, hip, and groin area over 20 months. The patient did not present any gastrointestinal symptoms and colonoscopy showed no abnormalities. Imaging revealed a liver abscess and multiple lesions with pneumatosis in the muscles of the right lower back region.
View Article and Find Full Text PDFRole of gut microbiota and in inflammatory bowel disease through immune-mediated synergistic actions.
World J Gastroenterol
December 2024
The Second Clinical Medical College, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang 330006, Jiangxi Province, China.
A recent study published in the , suggests that transplanting the gut microbiota from healthy donors can alleviate the pathological processes linked to inflammatory bowel disease (IBD), particularly Crohn's disease. In addition, that paper illustrates the effect of changes in the gut microbiota on IBD and points out that altered mesenteric adipose tissue caused by the gut microbiota and creeping fat lead to increased inflammation, which exacerbates IBD. Moreover, recent research has shown that the interaction between () and the gut microbiota is mediated through immune mechanisms, resulting in a synergistic impact on IBD.
View Article and Find Full Text PDFPerspectives on the extracellular matrix in inflammatory bowel disease and bowel decellularization protocols.
World J Exp Med
December 2024
Department of Anatomy, University of São Paulo, São Paulo 05508-000, Brazil.
The extracellular matrix (ECM) is a non-cellular three-dimensional structure present in all tissues that is essential for the intestinal maintenance, function and structure, as well as for providing physical support for tissue integrity and elasticity. ECM enables the regulation of various processes involved in tissue homeostasis, being vital for healing, growth, migration and cell differentiation. Structurally, ECM is composed of water, polysaccharides and proteins, such as collagen fibers and proteoglycans, which are specifically arranged for each tissue.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!